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Abbreviations
MS: Myeloid Sarcoma; AML: Acute Myeloid Leukemia; AlloHSCT: Allogeneic Hematopoietic 
Stem Cell Transplantation; MRI: Magnetic Nuclear Imaging
Background
Myeloid Sarcoma (MS), also known as granulocytic sarcoma or chloroma, is a rare hematologic 
cancer. It is characterized by proliferation of immature myeloid cells in one or more extramedullary 
tissues. MS has been reported in 2.5% to 9.1% of patients with Acute Myeloid Leukemia (AML). 
It can arise simultaneously (de novo AML related MS), following (secondary MS) or preceding 
(de novo extramedullary MS) the onset of bone marrow involvement [1,2]. More rarely MS could 
also be detected in the setting of myelodysplastic or myeloproliferative tumour. The most common 
involved location are soft tissues, skin, bones, periosteum, central nervous system and lymph nodes, 
but many other sites are described in multiple reports [3]. The diagnosis of MS required a tissue 
biopsy with immunohistochemical stains, fluorescence in situ hybridization and molecular analysis. 
The pathological differential diagnosis of MS is non-Hodgkin lymphoma, lymphoblastic leukemia, 
blastic plasmacytoid dendritic cell neoplasm and non-hematopoietic tumour [1,4].
Bone marrow biopsy and imaging to define the extension of tissue involvement are the other 
diagnostic and staging workup examinations.
The prognosis of MS is poor, both in the novo and in secondary subtypes, with a 5-year survival 
rate of 20% to 30%. Systemic chemotherapy is recommended also for isolated extramedullary form. 
Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) should be considered in every 
patient when it is practicable [2,5,6].
Case Presentation
A 24-year-old female presented a huge solid mass at the outer and central quadrants of the 
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left breast with sudden onset, apparently capsulated, 6 cm x 3 cm 
diameter, with a disomogeneous and vascularized structure at the 
ultrasound. Another mass, diameter 1.7 cm x 0.8 cm, was located 
at the inner quadrant. She had no history of breast cancer. Physical 
examination revealed petechiae at the lower limbs. MRI showed in 
the left breast, with prevalence in the upper quadrants, a mass of 
inhomogeneous enhancement, with diameters of 8.6 cm x 7.3 cm 
x 6.6 cm with disomogeneous content for the presence of central 
colliquated areas (Figure 1). Another lesion, diameter 2.4 cm, with 
the same features, was present at the lower quadrant. In the ipsilateral 
axilla there were two lymph nodes with thickened cortical of about 2 
cm in diameter.
An ultrasound guided needle biopsy of the largest breast mass 
was performed and histopathology showed a diagnosis of Myeloid 
Sarcoma. Histologically there was a proliferation of monomorphic 
little-medium size cells spread between residual ductal structures 
(Figure 2). The immunohistochemical analysis revealed that 
malignant cells were positive for myeloperoxidase, CD34, CD43 and 
CD68/KP1. Lymphoid (CD20/L26, CD79a, CD3, CD30/BERH2) 
and epithelial (cytokeratin) markers were negative. Peripheral blood 
analysis showed 46.000 leukocytes/mmc, haemoglobin level of 12,2 
gr/dl, 85.000 platelets/mmc and 1244 U/L of lactate dehydrogenase. 
Bone marrow aspirate and biopsy, together with molecular and 
cytogenetic assay, were consistent with a diagnosis of AML–M4Eo 
with inversion [16] (p13,q22) resulting in fusion gene CBFbeta-
MYH11. The study of cerebrospinal fluid was negative for localization 
of leukemia.
Induction chemotherapy was started with continuous infusion 
Cytarabine 100 mg/mq/days 1-10, Etoposide 50 mg/mq days 1-5 and 
Daunorubicin 50 mg/mq on days 1,3 and 5. The restaging showed a 
pattern of partial remission resulting from a bone marrow complete 
hematologic response associated with reduction of the breast mass 
(4.9 cm x 4.1 cm x 4 cm) on MRI. For the disease persistence in 
the extramedullary site, the patient was treated with a re-induction 
chemotherapy cycle consisted with Fludarabine 30 mg/mq days 
1-5, Cytarabine 2000 mg/mq days 1-5, Idarubicin 10 mg/mq days 
1-3 and Granulocyte colony stimulating factor from day -1 to day 
+5 obtaining a stable hematologic complete remission, decrease of 
minimal residual disease measured with quantitative real time PCR 
of chimeric transcript CBFbeta-MYH11 and further reduction of 
dimension of MS. After a subsequent cycle of Cytarabine 800 mg/
mq every 12 hrs on days 1-3 and autologous peripheral blood stem 
cells harvest also the MRD became negative. Therefore HSCT using a 
matched unrelated donor (MUD) 10/10 was performed. Sepsis from 
Klebsiella Pneumoniae was the only severe complication occurred 
during this long combined treatment. The patient doesn’t develop 
any sign of Graft Versus Host Disease. Nowadays, 40 months after 
transplantation, persists a picture of complete hematologic and 
molecular remission associated with MRI breast pattern of complete 
response. Follow up with periodic response assessment performed 
with MRI of the breast and bone marrow aspirate for morphological 
and molecular tests will continue.
Discussion
The breast is an uncommon location for de novo extramedullary 
myeloid tumor. MS of the breast is more commonly observed 
in the context of a myeloid neoplasm originating from the bone 
marrow during its natural history (de novo AML related MS or 
secondary MS) [7]. The prevalence of mammary gland involvement 
is 6% in a recent retrospective survey including 48 MS patients 
[2]. Gynecomastia or isolated breast mass may be the presentation 
of this entity. Histologically differential diagnoses of breast lesion 
are low grade Non Hodgkin Lymphoma, lobular carcinoma, 
undifferentiated carcinoma, malignant melanoma and inflammation 
[8]. Mammography, MRI and ultrasonography are commonly used 
to study a breast lump but MS is often indistinguishable from other 
benign tumour or lymphoma [9]. Diagnosis must be done only 
through tissue biopsy and immunohistochemistry. The prognosis 
of the disease is dismal and systemic chemotherapy demonstrates 
a fundamental role to improve the prognosis even for the isolated 
extramedullary localization. Radiotherapy or surgeries alone are 
inadequate. Furthermore, numerous retrospective surveys support 
the role of allo HSCT in the management of this rare hematologic 
neoplasm [2,3,6,10].
Conclusion
Primary involvement of the breast is a rare event in 
lymphoproliferative diseases and can be confounded with a primitive 
invasive breast cancer. In this case report, the young age of the patient 
and the absence of risk factors for breast malignancies suggest to 
avoid a surgical approach in the diagnostic-therapeutic pathway. The 
authors underline the importance of performing a needle biopsy in 
order to exclude all possible diagnosis of a primitive breast disease.
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Figure 1: Sagittal contrast enhanced MRI of the left breast shows an irregular 
marginated heterogeneously high enhancing mass, in the upper and central 
quadrants.
Figure 2: Medium-size myeloid tumor cells and inflammatory background 
with eosinophils. H&E 400x.
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